You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – X4 Pharmaceuticals has initiated a early-phase safety study of mavorixafor and ibrutinib (AbbVie's Imbruvica) for patients with CXCR4-mutated Waldenström’s macroglobulinemia (WM), a rare type of non-Hodgkin's lymphoma.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.